Mucosis B.V. appoints Dr. Govert Schouten as CEO.

--> Download the pdf

Groningen, The Netherlands, November 6, 2008.

Dutch biotechnology company Mucosis B.V. today announced the appointment of Dr. Govert Schouten to the position of Chief Executive Officer.

"We are very pleased to have a person with Dr. Schouten’s business and strategic background join Mucosis," said Dr. Willem Hazenberg, chairman of the supervisory board of Mucosis and partner at Mucosis’s lead investor BioGeneration Ventures B.V. "His extensive experience in the vaccine industry will make an important contribution to Mucosis's ambitious growth strategy for the coming years”.

Prior to joining Mucosis, Dr. Schouten served as vice president business development at publicly traded Crucell N.V. He was responsible for many of Crucell’s vaccine development partnerships, and for the successful licensing of Crucell’s technologies to the vaccine industry. Dr. Schouten holds an M.Sc in Biomedical Sciences and a Ph.D. in Virology from Leiden University.

Supervisory board Mucosis B.V.

For further information please contact:
Dr. Willem Hazenberg
BioGeneration Ventures B.V.
Tel: +31 (35) 6993000
hazenberg@mucosis.com
www.mucosis.com

About Mucosis

Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal
vaccines that can be applied via the nose or mouth. Mucosis’s lead product candidate is FluGEM®, an intranasal vaccine to prevent influenza. Mucosis’s vaccines are based
on the patented Mimopath® technology. Vaccines based on this technology can be administered needle-free, raise a more natural immune response, and provide a broader base of protection.

About Mimopath® technology

Mimopath® technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L. lactis bacteria into particles that can be loaded with antigens from viral, bacterial or parasitic origin. The antigen-covered particles form a vaccine that can be delivered via the nose or mouth, without the need for a needle. These vaccine particles raise protective immunity by activation of both the innate and adaptive immune system.

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >